Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:01:03 EDT Sun 28 Apr 2024
Enter Symbol
or Name
USA
CA



Q:ALKS - ALKERMES PLC - http://www.alkermes.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ALKS - Q0.121.95·27.520.124.68+0.241.01,016.724,5107,22724.55  24.80  24.3033.71  22.0116:20:00Apr 2415 min RT 2¢

Recent Trades - Last 10 of 7227
Time ETExPriceChangeVolume
16:20:00Q24.680.241,054
16:13:43Q24.680.2460
16:02:19Q24.680.24625
16:02:16Q24.680.242,312
16:02:15Q24.680.24151
16:01:48Q24.680.241
16:01:46Q24.680.24700
16:01:44Q24.680.24294
16:01:42Q24.680.24368
16:01:24Q24.680.242

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-24 07:00U:ALKSNews ReleaseAlkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1
2024-04-17 16:00U:ALKSNews ReleaseAlkermes to Report First Quarter Financial Results on May 1, 2024
2024-04-09 07:00U:ALKSNews ReleaseAlkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia
2024-04-08 07:00U:ALKSNews ReleaseAlkermes Presents Analyses From Long-Term Safety Study of LYBALVI(TM) (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society
2024-03-07 07:00U:ALKSNews ReleaseAlkermes Announces Appointment of Nancy S. Lurker to Board of Directors
2024-02-15 07:00U:ALKSNews ReleaseAlkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024
2024-02-08 16:00U:ALKSNews ReleaseAlkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 15, 2024
2024-01-03 16:00U:ALKSNews ReleaseAlkermes to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2024-01-03 07:00U:ALKSNews ReleaseAlkermes Announces Topline Results From Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI ‚ ® (olanzapine and samidorphan)
2023-12-27 11:47U:ALKSNews ReleaseEqual Opportunity and Respect: Diversity, Inclusion and Belonging at Alkermes
2023-12-20 12:20U:ALKSNews ReleaseCorporate Governance at Alkermes
2023-12-18 13:51U:ALKSNews ReleaseAlkermes' Commitment to Integrity and Compliance
2023-12-14 10:46U:ALKSNews ReleaseAlkermes' Culture of Employee Engagement and Wellness
2023-12-14 06:05U:ALKSNews ReleaseAlkermes plc Announces Agreement to Sell Athlone, Ireland Facility to Novo Nordisk
2023-12-11 14:31U:ALKSNews ReleasePatient Advocacy and Community Engagement at Alkermes
2023-11-29 15:18U:ALKSNews ReleasePharmaceuticals in the Environment
2023-11-21 16:00U:ALKSNews ReleaseAlkermes to Participate in Two Upcoming Investor Conferences
2023-11-21 11:49U:ALKSNews ReleaseEnvironmental Protection & Sustainability at Alkermes
2023-11-20 13:52U:ALKSNews ReleaseAlkermes Celebrates #Movember for Men ¢ € ™s Health Awareness Month
2023-11-16 10:32U:ALKSNews ReleaseAlkermes' Waste Optimization Highlights